Belluscura plc announced that, as anticipated, it has signed its second US distribution agreement for its X-PLO2R™ portable oxygen concentrator ("POC") portfolio. This is the next stage in establishing US-wide distribution coverage as part of the Group's commercialisation strategy. The distributor, located in the Midwest US, is a leading nationwide seller of supplemental oxygen and respiratory equipment. The distributor immediately issued its first purchase order with anticipated delivery of the X-PLO2R™ portable oxygen concentrator expected third quarter of 2021. As described in the Company's Admission Document, Belluscura's plan is to appoint distributors in the US to give US-wide coverage for the launch of the X-PLO2R™; and this is expected to occur in the second half of 2021 and into 2022. X-PLO2R™: The X-PLO2R™ weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world's first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other US Food & Drug Administration ("FDA") cleared POC in its class. The X-PLO2R™ can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO2R™ is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. In March 2021 Belluscura received 510(k) clearance from the FDA for the X-PLO2R™, which will be launched commercially in Third Quarter 2021. Additional products within the range will be launched within the next 12 months.